Skip to main content

Advertisement

Table 1 Associations between ALK rearrangement and the clinicopathologic characteristics of 487 patients with non-small cell lung cancer (NSCLC)

From: Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement

Characteristic Number of patients (%) ALK rearrangement [cases (%)] P
Negative Positive
Total 487 443 (91.0) 44 (9.0)  
Age
 ≤58 years 261 (53.6) 229 (51.7) 32 (72.7) 0.008
 >58 years 226 (46.4) 214 (48.3) 12 (27.3)  
Sex
 Male 303 (62.2) 279 (63.0) 24 (54.5) 0.271
 Female 184 (37.8) 164 (37.0) 20 (45.5)  
Histological type
 Adenocarcinoma 382 (78.4) 339 (76.5) 43 (97.7) 0.001
 Others 105 (21.6) 104 (23.5) 1 (2.3)  
Differentiation
 Well 206 (42.3) 187 (42.2) 19 (43.2) 0.901
 Poor 281 (57.7) 256 (57.8) 25 (56.8)  
Clinical stage
 I + II 226 (46.4) 213 (48.1) 13 (29.5) 0.019
 III + IV 261 (53.6) 230 (51.9) 31 (70.5)  
Smoking history
 Non-smoker 239 (49.1) 207 (46.7) 32 (72.7) 0.001
 Smoker 248 (50.9) 236 (53.3) 12 (27.3)  
EGFR mutation status     
 Negative 328 (67.4) 285 (64.3) 43 (97.7) <0.001
 Positive 159 (32.6) 158 (35.7) 1 (2.3)  
  1. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor.
  2. All values are presented as number of patients followed by percentages in the parentheses.